UK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientsThe UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 Share XUK okays early access to Gilead’s remdesivir in seriously ill COVID-19 patientshttps://pharmaphorum.com/news/uk-okays-early-access-to-gileads-remdesivir-in-seriously-ill-covid-19-patients/
Study sets benchmark for cost of repurposed coronavirus drugsScientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for Share XStudy sets benchmark for cost of repurposed coronavirus drugshttps://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/
Japan approves Gilead’s COVID-19 drug remdesivirJapan’s regulator has quickly approved Gilead’s remdesivir for patients with severe COVID-19, after the FDA allowed its use as Share XJapan approves Gilead’s COVID-19 drug remdesivirhttps://pharmaphorum.com/news/japan-approves-gileads-covid-19-drug-remdesivir/
Gilead working with generics firms to boost global supply of COVID-19 drugGilead has outlined plans to work with generics firms to rapidly increase production of its COVID-19 drug remdesivir to meet Share XGilead working with generics firms to boost global supply of COVID-19 drughttps://pharmaphorum.com/news/gilead-working-with-generics-firms-to-boost-global-supply-of-covid-19-drug/
First doses of Gilead’s COVID-19 drug remdesivir to arrive at US hospitalsThe first doses of Gilead’s COVID-19 drug remdesivir are set to arrive in US hospitals this week after Share XFirst doses of Gilead’s COVID-19 drug remdesivir to arrive at US hospitalshttps://pharmaphorum.com/news/first-doses-of-covid-19-drug-set-to-arrive-at-us-hospitals/
Covid-19 drug will be ‘affordable’ says Gilead, as it plans to ramp up productionGilead has outlined its plans to develop and ramp up production of its remdesivir COVID-19 drug, with CEO Daniel O’Day pledging to Share XCovid-19 drug will be ‘affordable’ says Gilead, as it plans to ramp up productionhttps://pharmaphorum.com/news/covid-19-drug-will-be-affordable-says-gilead-as-it-plans-to-ramp-up-production/
Gilead’s remdesivir hailed as COVID-19 standard of care after trial successIt’s official – Gilead’s remdesivir helps severely ill patients recover faster from COVID-19, according to results from a Share XGilead’s remdesivir hailed as COVID-19 standard of care after trial successhttps://pharmaphorum.com/news/phase-3-trial-confirms-five-day-dosing-regimen-for-gileads-covid-19-drug/
Disputed COVID-19 trial failure reports send Gilead shares downGilead’s COVID-19 drug remdesivir seemingly failed to produce an effect according to results of a Chinese clinical trial Share XDisputed COVID-19 trial failure reports send Gilead shares downhttps://pharmaphorum.com/news/disputed-covid-19-trial-failure-reports-send-gilead-shares-down/
Gilead shares jump after rethink of COVID-19 remdesivir trialShares in Gilead were up in premarket trading after the company announced it had increased the size of Share XGilead shares jump after rethink of COVID-19 remdesivir trialhttps://pharmaphorum.com/news/gilead-shares-jump-following-covid-19-trial-rethink/
